| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. | Chief Financial Officer | Common Stock | 11K | $203K | $18.41 | May 15, 2023 | Direct |
| Cibus, Inc. | Director | Class A Common Stock | 0 | $0 | $4.32 | Nov 18, 2024 | Direct |
| 4D Molecular Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 217K | May 15, 2023 | Direct | ||
| Cibus, Inc. | Director | Stock Option (Right-to-Buy) | 14.7K | Nov 20, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CBUS | Cibus, Inc. | Nov 20, 2024 | 1 | $0 | 4 | Nov 25, 2024 | Director |
| CBUS | Cibus, Inc. | Nov 18, 2024 | 0 | $0 | 3 | Nov 25, 2024 | Director |
| FDMT | 4D Molecular Therapeutics, Inc. | May 15, 2023 | 2 | $28.2K | 4 | May 16, 2023 | Chief Financial Officer |
| FDMT | 4D Molecular Therapeutics, Inc. | Feb 10, 2023 | 1 | $0 | 4 | Feb 14, 2023 | Chief Financial Officer |
| FDMT | 4D Molecular Therapeutics, Inc. | Dec 21, 2022 | 2 | $28.2K | 4 | Dec 22, 2022 | Chief Financial Officer |
| FDMT | 4D Molecular Therapeutics, Inc. | Sep 1, 2022 | 1 | $0 | 4 | Sep 6, 2022 | Chief Financial Officer |
| FDMT | 4D Molecular Therapeutics Inc. | Feb 1, 2022 | 1 | $0 | 4 | Feb 3, 2022 | Chief Financial Officer |